[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1111141T1 - Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων - Google Patents

Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων

Info

Publication number
CY1111141T1
CY1111141T1 CY20101100793T CY101100793T CY1111141T1 CY 1111141 T1 CY1111141 T1 CY 1111141T1 CY 20101100793 T CY20101100793 T CY 20101100793T CY 101100793 T CY101100793 T CY 101100793T CY 1111141 T1 CY1111141 T1 CY 1111141T1
Authority
CY
Cyprus
Prior art keywords
kdr
antibodies
human
particulars
special
Prior art date
Application number
CY20101100793T
Other languages
English (en)
Inventor
Zhenping Zhu
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27805075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111141(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of CY1111141T1 publication Critical patent/CY1111141T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η εφεύρεση παρέχει αντισώματα τα οποία δεσμεύονται σε KDR με μια συγγένεια συγκρίσιμη με ή υψηλότερη από ανθρώπινο VEGF, και τα οποία εξουδετερώνουν ενεργοποίηση του KDR. Τα αντισώματα περιλαμβάνουν ακέραιες ανοσοσφαιρίνες, μονοσθενή Fabs και απλής αλυσίδας αντισώματα, πολυσθενή απλής αλυσίδας αντισώματα, διασωμάτια, τρισωμάτια, και απλού τομέα αντισώματα. Η εφεύρεση περαιτέρω παρέχει νουκλεϊνικά οξέα και κύτταρα ξενιστές που κωδικοποιούν και εκφράζουν αυτά τα αντισώματα. Η εφεύρεση περαιτέρω παρέχει μία μέθοδο εξουδετέρωσης της ενεργοποίησης του KDR, μία μέθοδο αναστολής της αγγειογένεσης σε ένα θηλαστικό και μία μέθοδο αναστολής της ανάπτυξης όγκου σε ένα θηλαστικό.
CY20101100793T 2002-03-04 2010-08-30 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων CY1111141T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36178302P 2002-03-04 2002-03-04
EP03711375A EP1487856B1 (en) 2002-03-04 2003-03-04 Human antibodies specific to kdr and uses thereof

Publications (1)

Publication Number Publication Date
CY1111141T1 true CY1111141T1 (el) 2015-06-11

Family

ID=27805075

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20101100793T CY1111141T1 (el) 2002-03-04 2010-08-30 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
CY20111100630T CY1111629T1 (el) 2002-03-04 2011-06-29 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
CY2015018C CY2015018I1 (el) 2002-03-04 2015-04-30 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20111100630T CY1111629T1 (el) 2002-03-04 2011-06-29 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
CY2015018C CY2015018I1 (el) 2002-03-04 2015-04-30 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων

Country Status (18)

Country Link
US (2) US7498414B2 (el)
EP (3) EP1916001B1 (el)
JP (3) JP2005526506A (el)
AT (2) ATE510561T1 (el)
AU (1) AU2003213687A1 (el)
BE (1) BE2015C027I2 (el)
CA (1) CA2478169C (el)
CY (3) CY1111141T1 (el)
DE (1) DE60333554D1 (el)
DK (2) DK1487856T3 (el)
ES (2) ES2362931T3 (el)
FR (1) FR15C0034I2 (el)
HK (1) HK1118229A1 (el)
HU (1) HUS1500025I1 (el)
LU (1) LU92710I2 (el)
PT (2) PT1916001E (el)
SI (2) SI1916001T1 (el)
WO (1) WO2003075840A2 (el)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1916001T1 (sl) * 2002-03-04 2011-10-28 Imclone Llc Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
PL2383295T3 (pl) * 2003-12-10 2015-08-31 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
RS51908B (en) * 2004-02-06 2012-02-29 University Of Massachusetts CLOSTRIDIUM DIFFICILE TOXIN ANTIBODIES AND THEIR USES
MXPA06010715A (es) 2004-03-19 2007-05-23 Imclone Systems Inc Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
WO2006072620A1 (en) 2005-01-05 2006-07-13 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
EP2100618B1 (en) 2005-06-17 2014-02-12 ImClone LLC An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer
AU2006267097A1 (en) * 2005-07-13 2007-01-18 Beth Israel Deaconess Medical Center Methods of diagnosing and treating an inflammatory response
KR101371773B1 (ko) * 2005-12-15 2014-03-07 아스트라제네카 아베 암 치료를 위한, 안지오포이에틴-2 길항자와 ｖｅｇｆ-ａ,ｋｄｒ 및/또는 ｆｌｔ1 길항자의 조합물
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2008066752A2 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R & D Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
AU2008252854A1 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
JP5602625B2 (ja) 2007-06-26 2014-10-08 エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング 結合物質のディスプレイ
AU2008270274B2 (en) * 2007-07-03 2012-06-28 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
US8119130B2 (en) * 2007-07-25 2012-02-21 Medimmune Limited Targeted binding agents directed to KDR and uses thereof—035
UY31478A1 (es) 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20120183547A1 (en) * 2009-05-27 2012-07-19 Mount Sinai School Of Medicine Compositions and methods comprising vegfr-2 and vegfr-3 antagonists for the treatment of metastatic disease
EP2483301A1 (en) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
KR20120115348A (ko) * 2009-12-29 2012-10-17 예일 유니버시티 혈관 내피 성장 인자 (ｖｅｇｆ) 수용체의 억제제 및 그의 사용 방법
US9328162B2 (en) 2010-02-25 2016-05-03 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
EP2576615B1 (en) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2694552B1 (en) 2011-04-07 2017-10-11 Amgen Inc. Novel egfr binding proteins
JP6104897B2 (ja) 2011-06-02 2017-04-05 ダイアックス コーポレーション Ｆｃレセプター結合タンパク質
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
BR112014010774A2 (pt) 2011-11-02 2017-06-13 Apexigen Inc anticorpos anti-kdr e métodos de uso
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
WO2013151667A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CN105007939B (zh) * 2012-10-05 2018-10-19 卡德门企业有限公司 人抗vegfr-2/kdr抗体
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
ES2774964T3 (es) 2013-02-04 2020-07-23 Vascular Biogenics Ltd Métodos para inducir la capacidad de respuesta a un agente antiangiogénico
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
US9618523B2 (en) 2013-02-28 2017-04-11 Siemens Healthcare Diagnostics Inc. Methods and reagents for determining isomeric analytes
CN105705519A (zh) 2013-03-06 2016-06-22 梅里麦克制药股份有限公司 抗C-MET串联Fc双特异性抗体
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
TWI558399B (zh) * 2014-02-26 2016-11-21 美國禮來大藥廠 癌症之組合療法
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
MX2016014753A (es) 2014-05-15 2017-03-06 Bristol Myers Squibb Co Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno.
TWI569808B (zh) 2014-08-15 2017-02-11 禮來大藥廠 肝細胞腫瘤（ｈｃｃ）之治療
SG11201700855XA (en) 2014-08-28 2017-03-30 Eisai R&D Man Co Ltd High-purity quinoline derivative and method for manufacturing same
CN107531785B (zh) * 2014-10-07 2021-06-29 卡德门企业有限公司 人抗-vegfr-2/kdr抗体
TW201625304A (zh) 2014-10-24 2016-07-16 美國禮來大藥廠 泌尿上皮癌之療法
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
SG11201710198YA (en) 2015-06-16 2018-01-30 Eisai R&D Man Co Ltd Anticancer agent
DK3322731T3 (da) 2015-07-14 2021-03-08 Bristol Myers Squibb Co Fremgangsmåde til behandling af cancer ved hjælp af immun checkpoint-hæmmer; antistof der binder til programmed death-1-receptor (pd-1) eller programmed death ligand-1 (pd-l1)
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
WO2017117384A1 (en) * 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
US20190125864A1 (en) 2016-04-15 2019-05-02 Eli Lilly And Company Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma
US20190336599A1 (en) * 2016-04-15 2019-11-07 Eli Lilly And Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
EP4019019B1 (en) 2016-05-20 2024-02-07 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
US20190183972A1 (en) 2016-06-03 2019-06-20 Imclone Llc Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
WO2018069871A2 (en) * 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
WO2018081512A1 (en) 2016-10-28 2018-05-03 Imclone Llc Combination of an anti-vegfr-2 antibody and an anti-pd-l1 antibody for the treatment of cancer
CN110662770A (zh) * 2016-11-23 2020-01-07 比奥维拉迪维治疗股份有限公司 结合凝血因子ix和凝血因子x的双特异性抗体
CN106674349B (zh) 2017-03-07 2018-03-13 北京东方百泰生物科技有限公司 一种改进的抗vegfr‑2单克隆抗体
US11471457B2 (en) 2017-08-21 2022-10-18 Eli Lilly And Company Method of treating epithelial growth factor receptor (EGFR) T790M-positive non-small cell lung cancer by administering a combination of a VEGFR-2 antibody and osimertinib
EP3697451A1 (en) 2017-10-20 2020-08-26 Vascular Biogenics Ltd. Diagnostic methods for anti-angiogenic agent therapy
EP3814381A4 (en) 2018-06-29 2022-08-10 Gensun Biopharma Inc. TRI-SPECIFIC ANTAGONISTS
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
US20220154212A1 (en) 2019-03-13 2022-05-19 Vascular Biogenics Ltd. Methods of anti-tumor therapy
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
US20220296926A1 (en) 2019-07-31 2022-09-22 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
CA3154522A1 (en) 2019-10-15 2021-04-22 Christopher Carl Frye Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN111024949A (zh) * 2019-12-31 2020-04-17 上海博威生物医药有限公司 一种重组抗vegfr2单克隆抗体的生物活性分析方法及其应用
KR20230087451A (ko) 2020-09-02 2023-06-16 주식회사 파멥신 암 환자를 치료하기 위한 pd-1 길항제 및 vegfr-2에 대한 길항제의 조합 요법
CN114316064B (zh) * 2020-10-10 2024-07-26 广东菲鹏制药股份有限公司 融合蛋白及其应用
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2022256820A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
KR20240130705A (ko) 2021-12-30 2024-08-29 네오이뮨텍, 인코퍼레이티드 Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328695A (en) 1983-03-22 1994-07-12 Massachusetts Institute Of Technology Muscle morphogenic protein and use thereof
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4683295A (en) 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE4103975A1 (de) 1991-02-09 1992-08-13 Thomson Brandt Gmbh Verfahren zur verkuerzung der zugriffszeit
DK0531472T3 (da) 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
US20010021382A1 (en) 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5543503A (en) 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
ATE239506T1 (de) 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5693482A (en) 1992-07-27 1997-12-02 California Institute Of Technology Neural chest stem cell assay
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
JP3670302B2 (ja) 1993-07-23 2005-07-13 ファナック株式会社 射出成形機における可塑化の管理方法
US5599703A (en) 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
AT402796B (de) 1995-02-01 1997-08-25 Fritschi Apparatebau Schibindung
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
JP3658471B2 (ja) 1996-09-30 2005-06-08 株式会社日立製作所 電子ショッピングシステムにおける買物かご機能の提示方法及び電子ショッピングシステム
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
ATE331806T1 (de) 1996-11-21 2006-07-15 Kyowa Hakko Kogyo Kk Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
DE69838334T2 (de) 1997-06-18 2008-06-12 Merck & Co., Inc. (A New Jersey Corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
MXPA00011248A (es) 1998-05-15 2004-09-06 Imclone Systems Inc Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento.
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
US20030191055A1 (en) 1999-01-15 2003-10-09 Epstein Stephen E. Inhibiting development of microvessels withins coronary or peripheral vessel walls for restenosis/atherosclerosis prevention or therapy
EP1151002A4 (en) 1999-01-29 2002-05-02 Imclone Systems Inc KDR-SPECIFIC ANTIBODIES AND USES THEREOF
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
JP4926320B2 (ja) 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
JP2004501070A (ja) 2000-03-31 2004-01-15 イムクローン　システムズ　インコーポレイティド 血管内皮成長因子受容体アンタゴニストによる非固形哺乳類腫瘍の処理
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1515707A4 (en) 2001-06-20 2005-10-19 Imclone Systems Inc METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS AND OTHER INFLAMMATORY DISEASES
CA2452058A1 (en) 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US6519852B1 (en) 2001-07-26 2003-02-18 Yuecom Manufacturing Co., Ltd. Method of manufacturing an aluminum alloy wheel rim
SI1916001T1 (sl) * 2002-03-04 2011-10-28 Imclone Llc Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba
US6844779B2 (en) 2003-06-19 2005-01-18 The United States Of America As Represented By The Secretary Of The Air Force Optically isolated bias control circuit

Also Published As

Publication number Publication date
JP2012105667A (ja) 2012-06-07
FR15C0034I1 (fr) 2015-06-26
EP2298346A3 (en) 2011-11-16
DK1916001T3 (da) 2011-07-18
CY1111629T1 (el) 2015-10-07
US20090142358A1 (en) 2009-06-04
AU2003213687A8 (en) 2003-09-22
JP2005526506A (ja) 2005-09-08
PT1916001E (pt) 2011-07-18
CY2015018I2 (el) 2016-04-13
HK1118229A1 (en) 2009-02-06
SI1916001T1 (sl) 2011-10-28
EP2298346A2 (en) 2011-03-23
EP1916001A2 (en) 2008-04-30
ATE475431T1 (de) 2010-08-15
SI1487856T1 (sl) 2010-12-31
US7498414B2 (en) 2009-03-03
CY2015018I1 (el) 2016-04-13
LU92710I2 (fr) 2015-11-02
US8057791B2 (en) 2011-11-15
JP2009148298A (ja) 2009-07-09
PT1487856E (pt) 2010-09-29
EP1487856A2 (en) 2004-12-22
EP1487856B1 (en) 2010-07-28
DK1487856T3 (da) 2010-10-18
CA2478169A1 (en) 2003-09-18
WO2003075840A2 (en) 2003-09-18
JP4970483B2 (ja) 2012-07-04
EP1916001A3 (en) 2008-08-13
DE60333554D1 (de) 2010-09-09
CA2478169C (en) 2013-04-16
AU2003213687A1 (en) 2003-09-22
ATE510561T1 (de) 2011-06-15
JP5476404B2 (ja) 2014-04-23
ES2347543T3 (es) 2010-11-02
BE2015C027I2 (el) 2022-05-19
WO2003075840A3 (en) 2004-04-29
EP1487856A4 (en) 2006-08-23
HUS1500025I1 (hu) 2017-04-28
ES2362931T3 (es) 2011-07-15
EP1916001B1 (en) 2011-05-25
FR15C0034I2 (fr) 2016-08-26
US20050234225A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
CY1111141T1 (el) Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
CY1113037T1 (el) Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
CY1122412T1 (el) Ομοιοπολικα διασωματα καi χρησεις αυτων
CY1125133T1 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα a il-17
CY1124747T1 (el) Ανθρωπινα αντισωματα σε pd-1
CY1124341T1 (el) Ποντικοι me εξανθρωπισμενη καθολικη ελαφρια αλυσιδα
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
CY1120065T1 (el) Ανθρωπινα αντισωματα για ton erbb 2
CY1123535T1 (el) Υποκαταστατο θεραπευτικο τελικο σημειο για βασιζομενη σε anti-ctla-4 ανοσοθεραπεια ασθενειας
CY1121796T1 (el) Συνθεσεις μονοσθενεις για δεσμευση cd28 και μεθοδοι χρησης
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
CY1117203T1 (el) Διαλυτα «βαριας αλυσιδας-mono» αντισωματα
CO6351802A2 (es) Anticuerpos para ccr2
EA201070888A1 (ru) Антитела и их производные
CY1109143T1 (el) Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενες σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας
CY1110571T1 (el) Επιλεκτικα μεσα δεσμευσης της ανθρωπινης αγγειοποιητινης-2
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
BR112018068637A2 (pt) podocalixina e anticorpo relacionado a tra, métodos de preparação e usos como agente terapêutico anticancerígeno
DE602005010680D1 (de) Zusammensetzungen und verfahren zur induktion einer antitumorimmunität
MX2024005336A (es) Composiciones y metodos para la modulacion de inmunidad mediada por cadena beta.
AR104973A1 (es) Terapia de combinación para el tratamiento de cáncer
CY1114678T1 (el) Μεθοδοι για τον καθορισμο της δραστικοτητας της αδαλιμουμαμπης σε υποκειμενα εχοντα αγκυλοποιητικη σπονδυλιτιδα με τη χρησιμοποιηση των ctx-ii kai mmp3 ως βιοδεικτες
CY1113928T1 (el) Αντισωματα αντι-μυοστατινης